NRAS and melanoma: In contrast, while we showed that nilotinib treatment (24 h) induced RAF heterodimerization in MEKi-resistant NRAS-mutant melanoma cells, the result is inhibition of MEK/ERK and decreased coupling of NRAS and/or ERK to RAF rather than MEK/ERK activation.